You are hereJune 18, 2020
Study sheds light on why retinal ganglion cells are vulnerable to glaucoma
Durham, NC (June 18, 2020) - Millions of sufferers of glaucoma might someday benefit from a study released today in STEM CELLS in which a "disease in a dish" stem cell model was used to examine the mechanism in glaucoma that causes retinal ganglion cells (RGCs) to degenerate, resulting in loss of vision. The knowledge the study provides could result in new therapeutic approaches for this leading cause of blindness worldwide.
RGCs are a group of nerve cells located in the retina that send images to the brain and enable you to see. Glaucoma attacks these cells and, once they die, they are not replaced. However, why and how glaucoma causes the RGCs to degenerate is something of a mystery.
Stem cell modeling of the disease may shed light on this. Over the past decade, significant progress has been made using induced pluripotent stem cell (iPSC) technology to mimic glaucoma. This includes the generation of human RGCs from iPSCs, which led to the development of a disease model for primary open angle glaucoma (POAG) -- the most common form of glaucoma -- as well as an optic nerve model that demonstrated the supportive role of mTOR signaling in the regeneration of hRGC axons following chemical axotomy.
"However, both these models can be improved by characterizing the developmental trajectories of control and disease-specific RGCs," said Iqbal Ahmad, Ph.D., of the University of Nebraska Medical Center. He and his UNMC colleagues, Pooja Teotia, Ph.D., and Meng Niu, Ph.D., conducted the study reported on in STEM CELLS.
Dr. Ahmad continued, "This characterization includes the generation of hRGCs through normal developmental time and stages containing a complement of different subtypes, against which the developmental aspects of RGC abnormality in a disease model can be evaluated. Information about different RGC subtypes is not only important from a functional viewpoint, but also for understanding the underlying mechanism of glaucomatous degeneration, given the emerging evidence that the susceptibility and resistance of RGCs are subtype dependent."
In developing their model, the researchers used a single cell transcriptome analysis of human RGCs generated from normal (controls) and SIX6 risk allele iPS cells. (Previous studies have identified a significant association between POAG and SIX6, a gene that plays a role in ocular development.)
They observed that the developmental trajectories, beginning from neural stem cells to RGCs, were similar between SIX6 risk allele and control RGCs.
"However," Dr. Ahmad said, "we observed that the differentiation of SIX6 risk allele RGCs was stalled at the retinal progenitor cell stage, keeping them immature and deficient in subtype composition, compared to the controls. This was likely due to dysregulated mTOR and Notch signaling pathways that play an important role in RGC development. Furthermore," he added, "SIX6 risk allele RGCs, as compared to controls, expressed fewer genes corresponding to RGC subtypes that are preferentially resistant to degeneration.
"The immature phenotype of SIX6 risk allele RGCs with under-represented degeneration-resistant subtypes, may make them vulnerable to glaucomatous degeneration," he concluded.
"This study demonstrates the power of single cell sequencing methods for providing new insights into POAG pathology at the cellular and molecular level, which is necessary for formulation of new therapeutic approaches", said Dr. Jan Nolta, Editor-in-Chief of STEM CELLS. "This is truly remarkable and something that we could have not imagined was feasible thirteen years ago until the concept of patient specific iPSC disease modelling was invented. This is an excellent step forward and a phenomenon we will see becoming a daily reality in disease phenotyping and drug discovery."
The full article, "Mapping developmental trajectories and subtype diversity of normal and glaucomatous human retinal ganglion cells by single cell transcriptome analysis," can be accessed at https://stemcellsjournals.onlinelibrary.wiley.com/doi/abs/10.1002/stem.3238.
About the Journal: STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research. STEM CELLS is co-published by AlphaMed Press and Wiley.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA, and Belfast, Northern Ireland, publishes three internationally renowned peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST®m is devoted to community and hospital-based oncologists and physicians entrusted with cancer patient care. STEM CELLS TRANSLATIONAL MEDICINE®m is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
About Wiley: Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical and scholarly journals, combined with our digital learning, assessment and certification solutions, help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.